These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29194590)

  • 1. Effectiveness of Statins as Primary Prevention in People With Different Cardiovascular Risk: A Population-Based Cohort Study.
    Garcia-Gil M; Comas-Cufí M; Blanch J; Martí R; Ponjoan A; Alves-Cabratosa L; Petersen I; Marrugat J; Elosua R; Grau M; Ramos R
    Clin Pharmacol Ther; 2018 Oct; 104(4):719-732. PubMed ID: 29194590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Jarmul J; Pletcher MJ; Hassmiller Lich K; Wheeler SB; Weinberger M; Avery CL; Jonas DE; Earnshaw S; Pignone M
    Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004171. PubMed ID: 29650716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
    Waheed S; Pollack S; Roth M; Reichek N; Guerci A; Cao JJ
    Atherosclerosis; 2016 Dec; 255():193-199. PubMed ID: 27693004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry.
    Nanna MG; Navar AM; Wang TY; Mi X; Virani SS; Louie MJ; Lee LV; Goldberg AC; Roger VL; Robinson J; Peterson ED
    J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29739801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus.
    Malmborg M; Schmiegelow MDS; Gerds T; Schou M; Kistorp C; Torp-Pedersen C; Gislason G
    J Am Heart Assoc; 2021 Jul; 10(13):e020395. PubMed ID: 34151606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real world prescriptions in Taiwan.
    Chen ST; Huang ST; Shau WY; Lai CL; Li JZ; Fung S; Tse VC; Lai MS
    BMC Cardiovasc Disord; 2019 Mar; 19(1):62. PubMed ID: 30876393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.
    Stam-Slob MC; Visseren FL; Wouter Jukema J; van der Graaf Y; Poulter NR; Gupta A; Sattar N; Macfarlane PW; Kearney PM; de Craen AJ; Trompet S
    Clin Res Cardiol; 2017 Jan; 106(1):58-68. PubMed ID: 27554244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.
    Laleman N; Henrard S; van den Akker M; Goderis G; Buntinx F; Van Pottelbergh G; Vaes B
    BMC Cardiovasc Disord; 2018 Nov; 18(1):209. PubMed ID: 30400778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.
    Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?
    van Staa TP; Smeeth L; Ng ES; Goldacre B; Gulliford M
    Heart; 2013 Nov; 99(21):1597-602. PubMed ID: 23735939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study.
    Yebyo HG; Zappacosta S; Aschmann HE; Haile SR; Puhan MA
    BMC Cardiovasc Disord; 2020 Sep; 20(1):418. PubMed ID: 32942999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
    Mahabadi AA; Möhlenkamp S; Lehmann N; Kälsch H; Dykun I; Pundt N; Moebus S; Jöckel KH; Erbel R;
    JACC Cardiovasc Imaging; 2017 Feb; 10(2):143-153. PubMed ID: 27665163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.